Comparative Pharmacology
Head-to-head clinical analysis: AVANDARYL versus FORTAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDARYL versus FORTAMET.
AVANDARYL vs FORTAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of rosiglitazone (PPARγ agonist improving insulin sensitivity) and glimepiride (sulfonylurea stimulating insulin release from pancreatic beta cells).
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Rosiglitazone 4 mg/glimepiride 2 mg orally once daily, titrated based on glycemic response; maximum dose: rosiglitazone 8 mg/glimepiride 4 mg per day.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
None Documented
None Documented
Rosiglitazone: terminal half-life 3-4 hours (range 3-4.8 hours). Glimepiride: terminal half-life 5-8 hours (range 5-9 hours), with clinical duration of hypoglycemic effect up to 24 hours.
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Rosiglitazone: ~64% renal (as metabolites), ~23% fecal. Glimepiride: ~60% renal (60% of dose as metabolites, ~2% unchanged), ~40% fecal (as metabolites).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Category C
Category C
Antidiabetic
Antidiabetic